



Yusuf Tutar, Ph.D

Professor of Biochemistry

University of Health Sciences

Istanbul, Turkey

Phone: +90 506 458 0271

E-mail: yusuf.tutar@sbu.edu.tr

Education

Postdoc	2003-2005	Biochemistry and Genetics	National Institute of Health, NIDDK
Postdoc	2002-2003	Molecular Biology and Biochemistry	Rutgers University
Graduate PhD	1998-2003	Biochemistry	Texas Tech University
Graduate MSc	1996-1998	Biochemistry and Biophysics	Oregon State University
Under Graduate	1990-1994	Chemistry	Cumhuriyet University

Biography

Dr. Yusuf TUTAR obtained his M.Sc. and Ph.D. at Oregon State University and Texas Tech University respectively. He pursued his postdoctoral study at National Institutes of Health (NIH/NIDDK), USA. His research focuses on Biochemistry, Biophysics, Genetics, and Molecular Biology with specialization in the fields of protein structure-function, protein folding, prion, microrna, pseudogenes, molecular cancer, proteomics, genomics, protein expression and characterization by spectroscopic and calorimetric methods. Dr. Tutar currently continue his research on drug design at University of Health Sciences, Istanbul, Turkey.

Research Interest

- Molecular Cancer Research and epigenetic (RT-PCR and Microarray).
- Micro RNA, pseudogenes, and transfection.
- Prion, translation termination in eukaryotes, and transcription initiation in prokaryotes.
- Investigating structure-function relationship of biological macromolecules with biochemical, biophysical, genetics and molecular biological methods.
- Recombinant DNA technology, molecular sub-cloning, transformation and protein expression.
- Drug design, docking, molecular dynamics.

- Nanoparticles for drug targeting.
- Protein purification (Heat shock, Catabolite repressor and S100P proteins) and characterisation (Spectroscopy: Fluorescence, Luminescence, CD, FTIR; Calorimetry: Nano DSC and ITC; Chromatography: HPLC and FPLC; Other techniques: MALDI-TOF, GC, SPR)

Scientific Activities

Employment History

Prof. Dr.	2017-Current	Biochemistry Division, Faculty of Pharmacy, University of Health Sciences
Prof. Dr.	2013-2017	Biochemistry Division, Faculty of Pharmacy, Cumhuriyet University
Associate Prof.	2012-2013	Biochemistry Division, Faculty of Pharmacy, Cumhuriyet University
Associate Prof.	2008-2012	Biochemistry Division, Faculty of Medicine (Adjunct) Cumhuriyet University
Assistant Prof.	2005–2008	Biochemistry Department, Faculty of Science, Cumhuriyet University
TA/RA	1998–2003	Biochemistry Department, Texas Tech University

Publications

1. Tumor Targeting of Polymeric Nanoparticles Conjugated with Peptides, Saccharides, and Small Molecules for Anticancer Drugs, *Current Pharmaceutical Design*, 2017, 23, 1-9
2. Bayram B, Özgür A, Tutar L, Tutar Y.
3. Anti-Cancer Activities of Manganese Based Photoactivatable CO-Releasing Complexes (PhotoCORMs) with Benzimidazole Derivative Ligands. *Transition Metal Chem.*, 2017, In Press
4. Üstün E., Özgür A., Coskun KA, Demir S., Özdemir İ., Tutar Y.
5. Structure-Function Based Drug Design for Cancer Therapeutics *Current Pharmaceutical Biotechnology*, 2016, 17, 14, 1 Tutar Y.
6. Design, Synthesis, and evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis *Current Pharmaceutical Biotechnology*, 2016 17:14, 2-17. Gümüş M, Özgür, A, Tutar L, Koca İ, Tutar Y.
7. Regulation of oncogenic genes by Micro RNAs and pseudogenes in human lung cancer. Tutar Y, Özgür A, Tutar E, Tutar L, Pulliero A, Izzotti A. *Biomed Pharmacother.* 2016 Aug 20;83: 1182-1190
8. Co-Releasing Properties and Anti-Cancer Activities of Novel Manganese Complexes with Imidazole/Benzimidazole Ligands. *Journal of Coordination Chemistry*, 2016 Üstün E., Özgür A., Coskun KA, Demir S., Özdemir İ., Tutar Y.
9. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis. *Eur J Med Chem*, 2016:122:280-290. Koca İ, Özgür A, Er M, Gümüş M, Açıkalin Coşkun K, Tutar Y.
10. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications. *Anticancer Agents in Medicinal Chemistry*, 2015. [Epub ahead of print]. Ozgur A, Tutar Y. Therapeutic Targeting of microRNAs in Cancer: Future Perspectives. *Drug Development Research*, 2015. [Epub ahead of print] Tutar L, Tutar E, Ozgur A, Tutar Y.
11. A Novel Approach to Inhibit Heat Shock Response as Anticancer Strategy by Coumarine Compounds Containing Thiazole Skeleton. *Anticancer Agents in Medicinal Chemistry*, 2015. [Epub ahead of print]
12. PMID: 25846761. Koca I, Gumus M, Ozgur A, Disli A, Tutar Y.

13. Isolation and characterization of Heat Shock Protein 100 from *Toxoplasma gondii* RH Strain. *Experimental Parasitology*, 2015 Feb 26; 153:91-97. doi: 10.1016/j.exppara.2015.02.007. [Epub ahead of print] PMID: 25728232 Coskun KA, Tutar Y.
14. Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer. *Letters in Drug Design & Discovery* Vol. 12, 1, 2015. Ozgur A, Yenidunya E, Koca İ, Tutar Y.
15. Tumor Targeting of Polymeric Nanoparticles Conjugated with Peptides, Saccharides, and Small Molecules for Anticancer Drugs, *Current Pharmaceutical Design*, 2017, 23, 1-9
16. Bayram B, Özgür A, Tutar L, Tutar Y.
17. Anti-Cancer Activities of Manganese Based Photoactivatable CO-Releasing Complexes (PhotoCORMs) with Benzimidazole Derivative Ligands. *Transition Metal Chem.*, 2017, In Press
18. Üstün E., Özgür A., Coskun KA, Demir S., Özdemir İ., Tutar Y.
19. Structure-Function Based Drug Design for Cancer Therapeutics *Current Pharmaceutical Biotechnology*, 2016, 17, 14, 1 Tutar Y.
20. Design, Synthesis, and evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis *Current Pharmaceutical Biotechnology*, 2016 17, 14, 2-17. Gümüş M, Özgür, A, Tutar L, Koca İ, Tutar Y.
21. Regulation of oncogenic genes by MicroRNAs and pseudogenes in human lung cancer. Tutar Y, Özgür A, Tutar E, Tutar L, Pulliero A, Izzotti A. *Biomed Pharmacother.* 2016 Aug 20;83:1182-1190
22. Co-Releasing Properties and Anti-Cancer Activities of Novel Manganese Complexes with Imidazole/Benzimidazole Ligands. *Journal of Coordination Chemistry*, 2016 Üstün E., Özgür A., Coskun KA, Demir S., Özdemir I., Tutar Y.
23. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis. *Eur J Med Chem*, 2016;122:280-290. Koca İ, Özgür A, Er M, Gümüş M, Açikalin Coşkun K, Tutar Y.
24. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications. *Anticancer Agents in Medicinal Chemistry*, 2015. [Epub ahead of print]. Ozgur A, Tutar Y.
25. Therapeutic Targeting of microRNAs in Cancer: Future Perspectives. *Drug Development Research*, 2015. [Epub ahead of print] Tutar L, Tutar E, Ozgur A, Tutar Y.
26. A Novel Approach to Inhibit Heat Shock Response as Anticancer Strategy by Coumarine Compounds Containing Thiazole Skeleton. *Anticancer Agents in Medicinal Chemistry*, 2015. [Epub ahead of print] PMID: 25846761. Koca I, Gumus M, Ozgur A, Disli A, Tutar Y.
27. Isolation and characterization of Heat Shock Protein 100 from *Toxoplasma gondii* RH Strain. *Experimental Parasitology*, 2015 Feb 26; 153:91-97. doi: 10.1016/j.exppara.2015.02.007. [Epub ahead of print] PMID: 25728232 Coskun KA, Tutar Y.
28. Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer. *Letters in Drug Design & Discovery* Vol. 12, 1, 2015. Ozgur A, Yenidunya E, Koca İ, Tutar Y.
29. Prion; Mechanism and Function-Editorial. *Current Pharmaceutical Biotechnology*, 2014, Vol. 15, No. 11. Tutar Y.
30. Regulation of Heat Shock Proteins by miRNAs in Human Breast Cancer. *MicroRNA* Vol. 3, No.2, 2014. Ozgur A, Tutar L, Tutar Y.
31. Heat Shock Protein 90 Inhibitors in Oncology. *Current Proteomics*. 2014 July; 11 (2):1-9. Aykut O, Tutar Y.
32. Controlled Release and Drug Delivery in Diseases-Editorial. *Protein and Peptide Letters*. 2014, 21 (11):1. Tutar Y.
33. miRNA and Cancer; computational and experimental approaches *Curr Pharm Biotechnol.* 2014, 15 (5):429. Tutar Y.
34. miRNA and Cancer; an overview. *Curr Pharm Biotechnol.* 2014, 15 (5):430-437. Tutar L, Tutar E, Tutar Y.
35. Synthesis, molecular docking, and antitumoral activity of alnustone-like compounds against estrogen receptor alpha-positive human breast cancer. 2014, DOI: 10.3906/kim-1408-72. Küçüköglu K, Seçinti H, Özgür A, Seçen H, Tutar Y.
36. The Relation Between microRNA 221, 222, 146b and p27Kip1 Protein mRNA Secretions and Clinicopathological Parameters in Thyroid Cancers and the Alteration of miRNA Secretion in the presence of Hashimoto Thyroiditis. *Experimental and Clinical Endocrinology & Diabetes*. 2014 Mar; 122(3):137-143. Acibucu F, Dokmetas S, Tutar Y., Elagoz S, Kilicli F.

37. Dynamic Fluctuations Provide the Basis of a Conformational Switch Mechanism in Apo Cyclic AMP Receptor Protein. *Plos Computational Biology*. 2013 Jul; 9(7): e1003141. Fas B.A., Tutar Y., Haliloglu T.
38. Important Clinical Applications of Protein Based Nanoparticles. *Current Proteomics*. Vol 10 (4) 334-340, 2013. Ergul M, Ergul M, Tutar Y.
39. Isolation and Identification of Free Living Environmental Isolates of Amoebae Samples in Sivas, Turkey.
40. *Biomed Research International*. Volume 2013 (2013), Article ID 675145. Coskun A., Celik S, Tutar L, Elaldi N, Tutar Y.